arkinson disease (PD) is the second most common neurodegenerative disease in the United States, affecting approximately 1% of the population over 60 years of age. 17, 47 Although the development of levodopa in the 1960s revolutionized the treatment of PD, longterm studies have shown that approximately 40% of PD patients develop dyskinesias and motor fluctuations 4-6 years after treatment.
To this end we examined the Nationwide Inpatient Sample (NIS) for trends in surgical outcomes since FDA approval of DBS for PD in 2002.
Methods
The Nationwide Inpatient Sample was developed as part of the Healthcare Cost and Utilization Project (HCUP) from the Agency for Healthcare Research and Quality (AHRQ). It is the largest publicly available inpatient hospital database and catalogs discharge data from a stratified sample of approximately 20% of all nonfederal hospitals in the United States. For this study, we obtained the NIS data for an 8-year period ranging from 2002 to 2009. Because these data are drawn from a sample that includes all patients discharged from sampled hospitals, they can be used to estimate total annual case volumes, complications, and deaths, among other variables. The data set presented in this study is thus extrapolated using the weighting variables provided by HCUP.
Patient Population
International Classification of Diseases, 9th edition (ICD-9) codes were used to identify patients with a primary diagnosis of PD (332.0). Patients with PD and a primary procedure code for implantation or replacement of intracranial neurostimulator lead(s) (02.93) were then identified. The vast majority of patients identified with this combination of codes are undergoing DBS implantation for PD for the first time, although a small minority (< 5%) of these patients may be having leads replaced or revised.
Patient Characteristics
Age, sex, race, income quartile of the patient's zip code, and payer status were coded within the database. Medical comorbidities were defined using a modified version of the Elixhauser comorbidity score, 20 which excluded the two neurological comorbidity variables, "other neurological deficit" and "paralysis," such that the highest possible comorbidity score was 28. Payer status was defined by combining the primary and secondary payer variables and placing discharges into the exclusive categories: "private insurance," "Medicaid without private insurance," "Medicare with neither private insurance nor Medicaid," and "other." In records where race was not reported, patients were assumed to be white.
Hospital Characteristics
The NIS provides data on hospital size (small, medium, large), region (Northeast, Midwest, South, West), location (urban or rural), and teaching hospital status, as well as hospital caseload for a specific procedure by discharge number.
Complications/Outcomes Definitions
We identified a number of potential complications resulting from DBS for PD including hematoma complicating a procedure (998.1-998. 13 40-415.42) . The presence of any of these complications was included in an outcome variable we created entitled "any complication." We also examined secondary outcomes provided in the data set, including length of stay (LOS), discharge status, and mortality. Since hospitalization for this elective surgery should almost always result in discharge to home, we examined the status of all other outcomes (short-term hospital, "other transfer" [includes skilled nursing facility, intermediate care facility], and death), referred to as "non-home" discharge.
Statistical Analysis
We used univariate comparisons to illustrate trends in our data, primarily comparing the PD DBS population in different years or in hospitals with different caseloads. Analyses were performed with 2-sample t-tests or a chisquare test using built-in scripts (Matlab, Mathworks).
We used a mixed, or hierarchical, logistic regression model to analyze outcomes, given the nested data architecture of NIS. A hierarchical multivariate logistic regression model provides a multilevel analysis that can account for the fact that patients are clustered within hospitals rather than assuming independence of observations as a traditional linear logistic regression model would. We performed 3 separate regressions using SAS (SAS Institute) procedures GLIMMIX and MIXED to evaluate predictors of LOS, "non-home" discharge, and the presence of complications. Age, sex, race, mean income quartile of patient's zip code, payer status, and comorbidity score were coded as patientrelated variables with hospital caseload, geographic region, teaching status, and year performed as hospital or non-patient-related variables. Length of stay was log-transformed before inclusion in the regression model.
Results

Treatment Trends
In this data set, 18,313 DBS surgeries for PD were performed over an 8-year period (Fig. 1) . After an initial increase from approximately 2100 cases in 2002 to approximately 2700 cases in 2004, the number of cases dropped in 2005 and leveled off before beginning to increase in the final 2 years of the study. Baseline clinical information is provided in Table 1 . During the study period, the average age and comorbidity score of PD patients undergoing DBS surgery both demonstrated a statistically significant increase (respectively, from 62.1 to 63.8 years [p < 0.01] and from 0.64 to 0.98 [p = 0.03]) (Fig. 2) . Table 2 shows the characteristics of hospitals performing DBS for PD during the study period. We noted that the mean yearly caseload for hospitals performing the procedure decreased from 20.8 in 2002 to 10.9 in 2009 (Fig. 3) .
Safety outcomes, on the other hand, have remained essentially stable over time. Overall, 87% of patients were discharged routinely. Of the "non-routine" discharges, 5.39% involved the need for home health care, 7.22% involved discharge to a skilled nursing facility or other long-term care facility, and in 0.28% of the cases, the patients died. The percentage of non-home discharges (that is, discharges classified neither as "routine" nor to home health care) did not change significantly over the 8-year period (r = -0.57, p = 0.14; Fig. 4 ). Overall, 6.49% of patients experienced a perioperative complication during hospitalization. There was no statistically significant change in this complication rate over the study period (r = -0.24, p = 0.56; Fig.  5 ). Finally, the mean LOS was 2.23 days; as shown in Fig.  6 , LOS decreased significantly throughout this time period (from 2.45 to 2.02 days, p = 0.04).
Examination of Trends and Outcomes Using a Univariate Analysis
We next compared the top and bottom quartiles of discharges by hospital caseload in a univariate analysis (Table  3) . In this analysis, 958 and 977 surgeries for DBS occurred at bottom-and top-quartile (by discharge) hospitals, representing less than 13 surgeries and more than 36 surgeries per hospital annually, respectively. The characteristics of patients undergoing DBS surgery for PD at low-volume hospitals were virtually indistinguishable from those of patients treated at high-volume hospitals; the former group had slightly higher comorbidity scores (0.90 vs 0.75, p < 0.01) and a nonsignificant increase in age (64.01 years vs 63.39 years, p = 0.13). Patients undergoing DBS for PD at low-volume hospitals were also more likely to have private insurance (50.89% vs 44.49%, p < 0.01) rather than Medicare (43.05% vs 51.32%, p < 0.01).
Outcomes in the 2 groups were similar, with no statistically significant differences. There was a nonsignificant trend for the low-volume group to have lower complication rates (6.70% vs 8.02%, p = 0.20), shorter LOS (2.12 days vs 2.35 days, p = 0.06), and lower mortality rates (0.12 vs 0.30, p = 0.15), but they also had a lower percentage of routine discharges (85.31% vs 88.75%, p = 0.15).
To determine whether there was a caseload volume small enough to make a difference in safety outcomes (that is, a "floor effect"), we repeated the analyses comparing hospitals with annual caseloads of 10 or fewer and compared this population with the remaining hospitals finding no significant difference in complications, LOS, and non-home discharge. We also conducted this analysis with annual caseloads of 9 or fewer, 8 or fewer, and so on until 1, and found no significant differences. 
Evaluation of Outcomes Using a Hierarchical Logistic Regression Model
Examining factors important in non-home discharges, our multivariate model showed that increased age and increased comorbidity score were significantly associated with an increased percentage of non-home discharges (OR 1.67, 95% CI 1.42-1.96; and OR 1.32, 95% CI 1.17-1.49, respectively). Conversely, there was a significant association between the year in which DBS was performed and the number of non-home discharges, with more recent timing of DBS surgery being associated with reduced likelihood of non-home discharge (OR 0.92, 95% CI 0.85-0.99) ( Table 4 ). The overall percentage of non-home discharges, while varying, has not shown a statistically significant difference over time (mean 13.1%, range 8.7%-17.1%) (Fig. 4) . None of the hospital-related variables, including hospital caseload, had any effect on discharge status.
When we examined perioperative complications, the model showed that comorbidity score significantly contributed to an increase in complications (OR 1.25, 95% CI 1.10-1.43), whereas patient age and year the procedure was performed had no effect (OR 1.05, 95% CI 0.90-1.22; and OR 1.00, 95% CI 0.93-1.08, respectively) ( Table 4) . Again, none of the hospital-related variables contributed to complication rate.
Length of stay decreased significantly over the 8-year study period (Table 4 ). This multivariate model demonstrated that age and comorbidity score significantly predicted longer LOS (% change per 10 years 4.8%, 95% CI 3.0-6.7%; and % change per point 4.4%, 95% CI 2.6-6.2%, respectively). Importantly, we found that the year in which the procedure occurred was associated with a significant decrease in LOS such that more recent procedures resulted in shorter LOS (% change per year -3.1%, 95% CI, -4.1 to -2.0%). None of the hospital-related variables significantly contributed to LOS.
Because we suspected that the presence of complications may affect LOS and non-home discharge, we later included the presence of any complications in our model. The new model showed that even when we adjusted for complications, age and comorbidity significantly increased LOS and non-home discharge (Table 5) .
Discussion
Despite an older and more medically ill population being treated at lower-volume centers, LOS has steadily and found that hospital caseload significantly improved mortality rate and discharge status but not complication rates in an adjusted multivariate analysis. 21 In their study, however, DBS accounted for only one-third of all cases, as pallidotomies and thalamotomies were still the preferred surgeries of choice for PD. Although outcomes for the 3 different procedures were not statistically different in that study, 3 of 4 deaths occurred in the non-DBS groups, and the time period studied reflects the very beginning of DBS surgery for movement disorders.
In addition, these earlier data reflect a time in which surgery for PD was generally much more centralized. The top quartile in the study of Eskandar et al. included centers in which more than 121 surgeries for PD were performed each year while our top quartile consisted of centers where more than 36 cases were performed per year. After 2002, there was a significant diffusion of cases into lower-volume centers while safety outcomes remained stable. Our multivariate analysis indicates that hospital caseload has no effect on outcome. In addition, univariate analysis shows no statistically significant differences in outcomes between hospitals in the top versus bottom quartile by caseload. Patients at low-volume hospitals tend to have higher comorbidity scores yet have similar complication rates, non-home discharge rates, mortality rates, and LOS. Notably, for all of our safety outcomescomplications, non-home discharge, and LOS-this relationship held even for the hospitals with the lowest case volumes. These data suggest that lower-volume hospitals are expanding their criteria for DBS surgery by treating slightly older patients with more comorbidities without worsened safety outcomes.
Thus, perhaps due to the relative uniformity of DBS surgery for PD and exceedingly low baseline complication and mortality rates, these data demonstrate that patients with PD undergoing DBS surgery at lower-volume centers have similar safety outcomes as those treated at high-volume centers. Although not directly addressed in this study, prior studies have documented that patients in smaller, rural communities may not undergo DBS surgery for PD because they lack access to teaching hospitals where the majority of these procedures take place. 21 These data support the safety-though not efficacy-of DBS surgery at smaller-volume centers and should be used to attract patients with PD who are good candidates for surgery but may not live near a high-volume center. It may be tempting to interpret these data to mean that any center can perform DBS surgery with few perioperative complications. However, DBS is a highly specialized surgery that requires years of training to perform safely with clinical efficacy. Indeed, as previously discussed, Eskandar et al. demonstrated a robust case volume-outcome relationship at the beginning of the DBS era for movement disorders. Thus we find it more likely that, given the decentralization of care, our findings are a reflection of well-trained functional neurosurgeons moving into the community. While only one hypothesis, we consider it likely that neurosurgeons at lower-volume centers were trained at high-volume centers and modeled their practices according to their training. Thus, with suitable training and skills, maintaining a high-volume practice may not be critical for perioperative patient safety in DBS surgery.
As alluded to above, it is important to note that this study does not purport to measure clinical efficacy of DBS surgery. Thus, we cannot state that patients with PD undergoing DBS at low-volume, relatively inexperienced centers will have a functional outcome equivalent to what they might experience if treated at a higher-volume center. Comprehensive, surgeon-specific, prospective clinical data should be collected to clarify whether low-volume centers have outcomes similar to those of higher-volume centers with regard to efficacy and long-term complications of DBS surgery and surgical revision rates. With FDA approval of DBS for PD occurring recently, in 2002, it is perhaps not surprising to see that the year in which surgery was performed is the only factor significantly contributing to decreased LOS and non-home discharges over an 8-year period from 2002 to 2009. However, age and comorbidity scores of patients undergoing DBS for PD have also increased during this time period and are the only consistently significant variables that predict poor outcomes. Thus, there may be underlying variables contributing to improvements in outcome not captured in this data set. Improvements in anesthesia and perioperative medical care could certainly contribute to decreased LOS and mortality rates over time. Because complications strongly contribute to worsened outcomes, it is also possible that improvements in technology designed to avoid complications may be a factor. For exam- The greatest proportion of complications in this sample (~ 50%) involve mechanical lead complications. These have remained essentially unchanged since DBS leads were introduced in 2002. The data set does not specify the meaning of "mechanical complication." However, because the database is limited to the DBS electrode hospital implantation, the majority of these complications likely involve electrode malplacement or electrode damage. The rates of mechanical complications have not changed over time. To improve LOS and rates of home discharge, further improvements in electrode placement, such as intraoperative-MRI based placement, 38 as well as improvements in lead biomaterial composition and electrical connections should be made.
The NIS has become a frequently used tool to examine outcomes and trends for a multitude of diseases, and as such, its relative advantages and disadvantages should be discussed. The main advantages of the NIS are its size and its sampling. The NIS represents a sample of 20% of all inpatient admissions in the United States and thus represents an enormous data set. In addition, it is composed of all nonfederal hospitals from all regions of the country and is thus not limited to university centers, as are most published studies. With respect to this study, the NIS is a retrospective data set and by definition has associated limitations. The primary disadvantage is the lack of long-term complication measures and clinical outcome measures. This data set solely reflects short-term safety outcomes and cannot distinguish either the long-term safety or clinical efficacy profiles of high-versus low-volume centers; indeed, our study merely addresses the perioperative safety of highand low-volume centers and does not allow conclusions regarding procedural efficacy or differences in long-term functional outcome. Similarly, long-term complicationsincluding infection, skin erosions, hardware complications (for example, lead misplacement, migration, fractures) requiring revision, pulse generator malfunction, and psychi- atric sequelae-are not measured in our study. In addition, the NIS represents discharge-level data that rely on ICD-9 coding intended to serve primarily as a billing code. As such, our study depends on accuracy in coding that cannot be verified. Furthermore, ICD-9 coding cannot capture the full clinical context of PD (for example, patients' clinical presentation, medical comorbidities, surgical appropriateness) and surgical procedural variation (for example, nonstandard imaging practices, microelectrode recording, frame-based vs frameless procedures), which may have an impact on patient outcomes. Moreover, ICD-9 coding cannot capture the full array of short-term complications related to DBS, including neurological worsening, postoperative confusion, and vasovagal reactions. 25, 43 However, we believe the variable "length of stay" (LOS) will partially account for these unaddressed short-term complications. Lastly, DBS surgery for PD is aimed at improving patients' motor symptoms, and thus any study that can only examine mortality, LOS, and complication rates is limited in its scope.
Since FDA approval there have been many technological improvements in neurostimulation designed to improve either efficacy or patient comfort, and the effect of these advances would not be captured in this data set. For example, unilateral stimulator placement for bilateral electrodes, smaller-sized stimulators, rechargeable stimulators, and the ability for patients to control some stimulation parameters in response to a change in symptoms at home have been the mainstay of improvements over time. While there are studies supporting the efficacy of DBS for PD, questions regarding comparative efficacy of DBS at hospitals with varying caseload volumes remain to be explored. Furthermore, questions related to improvements in symptoms and reductions in medication, particularly as they relate to new technology, will have to be answered in another fashion.
Conclusions
In this large study of PD patients undergoing DBS surgery between 2002 and 2009, we found that safety outcomes improved or remained stable over time despite increasing age and comorbidity scores. Hospital caseload was not associated with improved safety outcomes. The diffusion of DBS surgery to smaller volume centers in the last decade has not resulted in poorer surgical safety outcomes. Whether DBS efficacy is similarly not impacted by hospital DBS volume remains to be examined. The only factor that was significantly associated with improved safety outcomes in our multivariate analysis was the year in which the surgery was performed, indicating that refinements in surgical technique and perioperative care likely contributed greatly to improved outcomes over time.
